Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 16.46 | EPS (ttm) | 14.63 | Insider Own | 4.07% | Shs Outstand | 62.82M | Perf Week | -2.06% |
| Market Cap | 15.12B | Forward P/E | 9.34 | EPS next Y | 25.77 | Insider Trans | -4.90% | Shs Float | 61.98M | Perf Month | -4.53% |
| Enterprise Value | 17.32B | PEG | 1.97 | EPS next Q | 6.47 | Inst Own | - | Short Float | 7.46% | Perf Quarter | 7.16% |
| Income | 940.00M | P/S | 3.29 | EPS this Y | 71.10% | Inst Trans | - | Short Ratio | 5.02 | Perf Half Y | 32.42% |
| Sales | 4.60B | P/B | 3.15 | EPS next Y | 2.97% | ROA | 8.49% | Short Interest | 4.62M | Perf YTD | 41.61% |
| Book/sh | 76.44 | P/C | 6.87 | EPS next 5Y | 8.37% | ROE | 21.37% | 52W High | 266.39 -9.63% | Perf Year | 85.84% |
| Cash/sh | 35.02 | P/FCF | 10.01 | EPS past 3/5Y | - | ROIC | 14.46% | 52W Low | 125.79 91.38% | Perf 3Y | 79.50% |
| Dividend Est. | - | EV/EBITDA | 11.72 | Sales past 3/5Y | 5.27% 12.54% | Gross Margin | 84.67% | Volatility | 1.86% 2.62% | Perf 5Y | 78.84% |
| Dividend TTM | - | EV/Sales | 3.76 | EPS Y/Y TTM | 69.13% | Oper. Margin | 31.05% | ATR (14) | 6.40 | Perf 10Y | 97.93% |
| Dividend Ex-Date | - | Quick Ratio | 1.58 | Sales Y/Y TTM | 13.07% | Profit Margin | 20.45% | RSI (14) | 43.64 | Recom | 2.10 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.78 | EPS Q/Q | 169.21% | SMA20 | -2.35% | Beta | 0.37 | Target Price | 289.50 |
| Payout | 0.00% | Debt/Eq | 1.25 | Sales Q/Q | 15.49% | SMA50 | -3.31% | Rel Volume | 2.53 | Prev Close | 243.84 |
| Employees | 2,890 | LT Debt/Eq | 1.01 | Earnings | Nov 04 | SMA200 | 15.49% | Avg Volume | 876.73K | Price | 240.74 |
| IPO Date | Jun 01, 2007 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -7.53% 8.42% | Net Debt/EBITDA | 1.89 | Volume | 2,214,140 | Change | -1.27% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Sep-11-26 | Reiterated | UBS | Buy | $315 → $337 |
| Sep-10-26 | Reiterated | Barclays | Overweight | $270 → $271 |
| Aug-28-26 | Reiterated | RBC Capital | Outperform | $277 → $299 |
| Aug-26-26 | Reiterated | RBC Capital | Outperform | $194 → $277 |
| Aug-26-26 | Reiterated | Canaccord Genuity | Buy | $290 → $300 |
| Aug-26-26 | Reiterated | Deutsche Bank | Buy | $287 → $300 |
| Aug-26-26 | Reiterated | Morgan Stanley | Overweight | $283 → $322 |
| Aug-26-26 | Reiterated | Truist Securities | Buy | $300 → $281 |
| Aug-26-26 | Reiterated | Needham | Buy | $292 → $310 |
| Aug-11-26 | Reiterated | Morgan Stanley | Overweight | $280 → $283 |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 4,601 | 4,268 | 4,069 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 705 | 503 | 446 | — | — | — | — | — | — | |
| Gross Profit | 3,896 | 3,764 | 3,623 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 1,679 | 1,809 | 1,385 | — | — | — | — | — | — | |
| Research and Development | 754 | 783 | 884 | — | — | — | — | — | — | |
| Other Operating Expense | 35 | 948 | 638 | — | — | — | — | — | — | |
| Operating Income | 1,429 | 224 | 717 | — | — | — | — | — | — | |
| Interest Expense | 194 | 195 | 238 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -507 | -658 | -10 | — | — | — | — | — | — | |
| Net Income Before Taxes | 727 | -629 | 469 | — | — | — | — | — | — | |
| Income Taxes | -213 | -272 | -91 | — | — | — | — | — | — | |
| Consolidated Net Income | 940 | -356 | 560 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 940 | -356 | 560 | — | — | — | — | — | — | |
| Net Income | 940 | -356 | 560 | — | — | — | — | — | — | |
| EPS (Recurring) | 15.20 | -5.84 | 9.06 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 15.20 | -5.84 | 9.06 | — | — | — | — | — | — | |
| EPS (Diluted) | 14.63 | -5.84 | 8.65 | — | — | — | — | — | — | |
| EBITDA | 1,477 | 108 | 1,522 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 16.46 | — | 14.24 | — | — | — | — | — | — | |
| Price To Sales Ratio | 3.30 | 2.43 | 1.88 | — | — | — | — | — | — | |
| Gross Margin | 84.68 | 88.19 | 89.04 | — | — | — | — | — | — | |
| Operating Margin | 31.06 | 5.25 | 17.62 | — | — | — | — | — | — | |
| Net Margin | 20.43 | -8.34 | 13.76 | — | — | — | — | — | — | |
| Shares Outstanding | 63 | 61 | 62 | — | — | — | — | — | — | |
| Market Capitalization | 15,167 | 10,370 | 7,635 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Patil Neena M | EVP & Chief Legal Officer | Sep 10 '26 | Sale | 240.94 | 1,200 | 289,128 | 47,671 | Sep 14 |
| GALA RENEE D | President & CEO | Sep 08 '26 | Sale | 243.03 | 2,000 | 486,060 | 143,394 | Sep 10 |
| COZADD BRUCE C | Director | Sep 01 '26 | Sale | 250.13 | 6,000 | 1,500,780 | 351,875 | Sep 02 |
| Iannone Robert | EVP, Global Head of R&D & CMO | Aug 27 '26 | Option Exercise | 125.84 | 57,500 | 7,235,860 | 142,607 | Aug 31 |
| Iannone Robert | EVP, Global Head of R&D & CMO | Aug 27 '26 | Sale | 249.70 | 76,921 | 19,207,097 | 65,686 | Aug 31 |
| COZADD BRUCE C | Director | Aug 03 '26 | Sale | 252.98 | 6,000 | 1,517,880 | 360,682 | Aug 05 |
| COZADD BRUCE C | Director | Jul 01 '26 | Sale | 240.47 | 6,000 | 1,442,820 | 366,682 | Jul 06 |
| Smith Mark Douglas | Director | Jun 15 '26 | Sale | 230.55 | 1,157 | 266,746 | 9,680 | Jun 17 |
| Patil Neena M | EVP & Chief Legal Officer | Jun 10 '26 | Sale | 231.83 | 1,200 | 278,196 | 51,549 | Jun 12 |
| Mulligan Seamus | Director | May 28 '26 | Option Exercise | 138.08 | 3,415 | 471,543 | 1,183,028 | Jun 01 |
| Pearce Samantha | EVP, Chief Commercial Officer | May 28 '26 | Sale | 235.41 | 6,907 | 1,625,977 | 50,272 | Jun 01 |
| Patil Neena M | EVP & Chief Legal Officer | May 28 '26 | Sale | 236.97 | 1,192 | 282,468 | 52,626 | Jun 01 |
| Pearce Samantha | EVP, Chief Commercial Officer | May 28 '26 | Option Exercise | 109.45 | 6,907 | 755,971 | 57,179 | Jun 01 |
| Winningham Rick E | Director | May 22 '26 | Option Exercise | 138.08 | 3,415 | 471,543 | 12,308 | May 27 |
| Winningham Rick E | Director | May 22 '26 | Sale | 241.57 | 2,741 | 662,143 | 9,567 | May 27 |